Search Results

Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a significant concern in the analgesic field.

Tris Pharma on Wednesday secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for attention deficit hyperactivity disorder in pediatric patients.

Tris Pharma, Inc. has entered into a licensing agreement with Braingaze Ltd. and launched its new business, Tris Digital Health, which will focus on the development and commercialization of digital diagnostic and therapeutic products for neurological health conditions.

Tris Pharma, Inc. today announced the appointment of Michael Magee as vice president, quality and compliance.

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

Tris Pharma, Inc. today announced the appointment of Franchesca Fowler, JD, as chief compliance officer and vice president, general counsel.

Tris Pharma, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved ONYDA™ XR (clonidine hydrochloride), a once-a-day extended-release oral suspension with nighttime dosing, for the treatment of ADHD as a monotherapy or as an adjunctive therapy to approved central nervous system (CNS) stimulant medications in pediatric patients six years and older.